BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 10686023)

  • 1. Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia.
    Marais DJ; Rose RC; Lane C; Kay P; Nevin J; Denny L; Soeters R; Dehaeck CM; Williamson AL
    J Med Virol; 2000 Apr; 60(4):403-10. PubMed ID: 10686023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa.
    Marais D; Rose RC; Williamson AL
    J Med Virol; 1997 Feb; 51(2):126-31. PubMed ID: 9021543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.
    de Gruijl TD; Bontkes HJ; Walboomers JM; Coursaget P; Stukart MJ; Dupuy C; Kueter E; Verheijen RH; Helmerhorst TJ; Duggan-Keen MF; Stern PL; Meijer CJ; Scheper RJ
    J Gen Virol; 1999 Feb; 80 ( Pt 2)():399-408. PubMed ID: 10073700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia.
    Einstein MH; Studentsov YY; Ho GY; Fazzari M; Marks M; Kadish AS; Goldberg GL; Runowicz CD; Burk RD
    Int J Cancer; 2007 Jan; 120(1):55-9. PubMed ID: 17036320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia.
    de Gruijl TD; Bontkes HJ; Walboomers JM; Schiller JT; Stukart MJ; Groot BS; Chabaud MM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
    J Natl Cancer Inst; 1997 May; 89(9):630-8. PubMed ID: 9150187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgG antibodies to human papillomavirus 16, 52, 58, and 6 L1 capsids: case-control study of cervical intraepithelial neoplasia in Japan.
    Matsumoto K; Yoshikawa H; Yasugi T; Nakagawa S; Kawana K; Takeoka A; Yaegashi N; Iwasaka T; Kanazawa K; Taketani Y; Kanda T
    J Med Virol; 2003 Mar; 69(3):441-6. PubMed ID: 12526056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma.
    Sun Y; Eluf-Neto J; Bosch FX; Muñoz N; Walboomers JM; Meijer CJ; Shah KV; Clayman B; Viscidi RP
    Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):935-40. PubMed ID: 10548324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
    Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
    Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16.
    Bontkes HJ; de Gruijl TD; Walboomers JM; Schiller JT; Dillner J; Helmerhorst TJ; Verheijen RH; Scheper RJ; Meijer CJ
    J Gen Virol; 1999 Feb; 80 ( Pt 2)():409-417. PubMed ID: 10073701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serological and T-helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls.
    Luxton JC; Rose RC; Coletart T; Wilson P; Shepherd PS
    J Gen Virol; 1997 Apr; 78 ( Pt 4)():917-23. PubMed ID: 9129666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions.
    Strickler HD; Schiffman MH; Eklund C; Glass AG; Scott DR; Sherman ME; Wacholder S; Kurman RJ; Manos MM; Schiller JT; Dillner J
    Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):183-8. PubMed ID: 9138661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferative T-cell responses to human papillomavirus type 16 E5 are decreased amongst women with high-grade neoplasia.
    Gill DK; Bible JM; Biswas C; Kell B; Best JM; Punchard NA; Cason J
    J Gen Virol; 1998 Aug; 79 ( Pt 8)():1971-6. PubMed ID: 9714245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia.
    Matsumoto K; Yasugi T; Oki A; Fujii T; Nagata C; Sekiya S; Hoshiai H; Taketani Y; Kanda T; Kawana T; Yoshikawa H
    Cancer Lett; 2006 Jan; 231(2):309-13. PubMed ID: 16399232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles.
    Tachezy R; Hamsíková E; Hájek T; Mikysková I; Smahel M; Van Ranst M; Kanka J; Havránková A; Rob L; Guttner V; Slavík V; Anton M; Kratochvíl B; Kotrsová L; Vonka V
    J Med Virol; 1999 Aug; 58(4):378-86. PubMed ID: 10421405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia.
    Marais DJ; Best JM; Rose RC; Keating P; Soeters R; Denny L; Dehaeck CM; Nevin J; Kay P; Passmore JA; Williamson AL
    J Med Virol; 2001 Sep; 65(1):149-54. PubMed ID: 11505457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer.
    Combita AL; Bravo MM; Touzé A; Orozco O; Coursaget P
    Int J Cancer; 2002 Feb; 97(6):796-803. PubMed ID: 11857357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction.
    Lehtinen M; Luukkaala T; Wallin KL; Paavonen J; Thoresen S; Dillner J; Hakama M
    J Clin Virol; 2001 Aug; 22(1):117-24. PubMed ID: 11418359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection.
    Clerici M; Merola M; Ferrario E; Trabattoni D; Villa ML; Stefanon B; Venzon DJ; Shearer GM; De Palo G; Clerici E
    J Natl Cancer Inst; 1997 Feb; 89(3):245-50. PubMed ID: 9017005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions.
    Rocha-Zavaleta L; Ambrosio JP; Mora-Garcia ML; Cruz-Talonia F; Hernandez-Montes J; Weiss-Steider B; Ortiz-Navarrete V; Monroy-Garcia A
    J Gen Virol; 2004 Sep; 85(Pt 9):2643-2650. PubMed ID: 15302958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
    Kirnbauer R; Hubbert NL; Wheeler CM; Becker TM; Lowy DR; Schiller JT
    J Natl Cancer Inst; 1994 Apr; 86(7):494-9. PubMed ID: 8133532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.